The effect of 6-thioguanine on alternative splicing and antisense-mediated exon skipping treatment for duchenne muscular dystrophy

PLoS Currents

Volumn , Issue DEC, 2012, Pages 1-12

  Verhaart, Ingrid E C ^a   Aartsma Rus, Annemieke ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; DYSTROPHIN; MORPHOLINO OLIGONUCLEOTIDE; TIOGUANINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DUCHENNE MUSCULAR DYSTROPHY; EXON SKIPPING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA ANALYSIS; SEQUENCE ANALYSIS; WESTERN BLOTTING;

EID: 84873472792     PISSN: None     EISSN: 21573999     Source Type: Journal    
DOI: 10.1371/currents.md.597d700f92eaa70de261ea0d91821377.     Document Type: Article

References (33)

1. Emery AE: The muscular dystrophies. Lancet 23-2-2002;359:687-695.
2. Yazaki M, Yoshida K, Nakamura A, Koyama J, Nanba T, Ohori N, Ikeda S: Clinical characteristics of aged Becker muscular dystrophy patients with onset after 30 years. Eur Neurol 1999;42:145-149.
3. Blake DJ, Weir A, Newey SE, Davies KE: Function and genetics of dystrophin and dystrophin-related proteins in muscle. Physiol Rev 2002;82:291-329.
4. Muntoni F, Torelli S, Ferlini A: Dystrophin and mutations: one gene, several proteins, multiple phenotypes. Lancet Neurol 2003;2:731-740.
5. Verhaart IE, Aartsma-Rus A: Gene therapy for Duchenne muscular dystrophy. Curr Opin Neurol 16-8-2012.
6. Aartsma-Rus A: Overview on AON design. Methods Mol Biol 2012;867:117-129.
7. Wu B, Li Y, Morcos PA, Doran TJ, Lu P, Lu QL: Octa-guanidine morpholino restores dystrophin expression in cardiac and skeletal muscles and ameliorates pathology in dystrophic mdx mice. Mol Ther 2009;17:864-871.
8. Yin H, Moulton HM, Seow Y, Boyd C, Boutilier J, Iverson P, Wood MJ: Cellpenetrating peptide-conjugated antisense oligonucleotides restore systemic muscle and cardiac dystrophin expression and function. Hum Mol Genet 15-12-2008;17:3909-3918.
9. Moulton HM, Moulton JD: Morpholinos and their peptide conjugates: therapeutic promise and challenge for Duchenne muscular dystrophy. Biochim Biophys Acta 2010;1798:2296-2303.
10. Wu B, Lu P, Cloer C, Shaban M, Grewal S, Milazi S, Shah SN, Moulton HM, Lu QL: Long-Term Rescue of Dystrophin Expression and Improvement in Muscle Pathology and Function in Dystrophic mdx Mice by Peptide-Conjugated Morpholino. Am J Pathol 2012;181:392-400.
11. Shetty RS, Gallagher CS, Chen YT, Hims MM, Mull J, Leyne M, Pickel J, Kwok D, Slaugenhaupt SA: Specific correction of a splice defect in brain by nutritional supplementation. Hum Mol Genet 1-11-2011;20:4093-4101.
12. Zhou J, Zheng X, Shen H: Targeting RNA-splicing for SMA treatment. Mol Cells 2012;33:223-228.
13. Nishida A, Kataoka N, Takeshima Y, Yagi M, Awano H, Ota M, Itoh K, Hagiwara M, Matsuo M: Chemical treatment enhances skipping of a mutated exon in the dystrophin gene. Nat Commun 2011;2:308.
14. Sicinski P, Geng Y, Ryder-Cook AS, Barnard EA, Darlison MG, Barnard PJ: The molecular basis of muscular dystrophy in the mdx mouse: a point mutation. Science 30-6-1989;244:1578-1580.
15. Hu Y, Wu B, Zillmer A, Lu P, Benrashid E, Wang M, Doran T, Shaban M, Wu X, Lu QL: Guanine analogues enhance antisense oligonucleotide-induced exon skipping in dystrophin gene in vitro and in vivo. Mol Ther 2010;18:812-818.
16. Elion GB: The purine path to chemotherapy. Science 7-4-1989;244:41-47.
17. Zhu CH, Mouly V, Cooper RN, Mamchaoui K, Bigot A, Shay JW, Di Santo JP, Butler-Browne GS, Wright WE: Cellular senescence in human myoblasts is overcome by human telomerase reverse transcriptase and cyclindependent kinase 4: consequences in aging muscle and therapeutic strategies for muscular dystrophies. Aging Cell 2007;6:515-523.
18. Aartsma-Rus A, Janson AA, Kaman WE, Bremmer-Bout M, Den Dunnen JT, Baas F, van Ommen GJ, van Deutekom JC: Therapeutic antisense-induced exon skipping in cultured muscle cells from six different DMD patients. Hum Mol Genet 15-4-2003;12:907-914.
19. Mann CJ, Honeyman K, McClorey G, Fletcher S, Wilton SD: Improved antisense oligonucleotide induced exon skipping in the mdx mouse model of muscular dystrophy. J Gene Med 2002;4:644-654.
20. Spitali P, Heemskerk H, Vossen RH, Ferlini A, Den Dunnen JT, 't Hoen PA, Aartsma-Rus A: Accurate quantification of dystrophin mRNA and exon skipping levels in duchenne muscular dystrophy. Lab Invest 2010;90:1396-1402.
21. Heemskerk HA, de Winter CL, de Kimpe SJ, van Kuik-Romeijn P, Heuvelmans N, Platenburg GJ, van Ommen GJ, van Deutekom JC, Aartsma-Rus A: In vivo comparison of 2'-O-methyl phosphorothioate and morpholino antisense oligonucleotides for Duchenne muscular dystrophy exon skipping. J Gene Med 2009;11:257-266.
22. Chan JH, Lim S, Wong WS: Antisense oligonucleotides: from design to therapeutic application. Clin Exp Pharmacol Physiol 2006;33:533-540.
23. Amantana A, Iversen PL: Pharmacokinetics and biodistribution of phosphorodiamidate morpholino antisense oligomers. Curr Opin Pharmacol 2005;5:550-555.
24. Swann PF, Waters TR, Moulton DC, Xu YZ, Zheng Q, Edwards M, Mace R: Role of postreplicative DNA mismatch repair in the cytotoxic action of thioguanine. Science 23-8-1996;273:1109-1111.
25. Waters TR, Swann PF: Cytotoxic mechanism of 6-thioguanine: hMutSalpha, the human mismatch binding heterodimer, binds to DNA containing S6-methylthioguanine. Biochemistry 4-3-1997;36:2501-2506.
26. Somerville L, Krynetski EY, Krynetskaia NF, Beger RD, Zhang W, Marhefka CA, Evans WE, Kriwacki RW: Structure and dynamics of thioguanine-modified duplex DNA. J Biol Chem 10-1-2003;278:1005-1011.
27. Ling YH, Chan JY, Beattie KL, Nelson JA: Consequences of 6-thioguanine incorporation into DNA on polymerase, ligase, and endonuclease reactions. Mol Pharmacol 1992;42:802-807.
28. Marathias VM, Sawicki MJ, Bolton PH: 6-Thioguanine alters the structure and stability of duplex DNA and inhibits quadruplex DNA formation. Nucleic Acids Res 15-7-1999;27:2860-2867.
29. Uribe-Luna S, Quintana-Hau JD, Maldonado-Rodriguez R, Espinosa-Lara M, Beattie KL, Farquhar D, Nelson JA: Mutagenic consequences of the incorporation of 6-thioguanine into DNA. Biochem Pharmacol 1-8-1997;54:419-424.
30. Hann IM, Stevens RF, Goldstone AH, Rees JK, Wheatley K, Gray RG, Burnett AK: Randomized comparison of DAT versus ADE as induction chemotherapy in children and younger adults with acute myeloid leukemia. Results of the Medical Research Council's 10th AML trial (MRC AML10). Adult and Childhood Leukaemia Working Parties of the Medical Research Council. Blood 1-4-1997;89:2311-2318.
31. Preisler H, Davis RB, Kirshner J, Dupre E, Richards F, III, Hoagland HC, Kopel S, Levy RN, Carey R, Schulman P,.: Comparison of three remission induction regimens and two postinduction strategies for the treatment of acute nonlymphocytic leukemia: a cancer and leukemia group B study. Blood 1987;69:1441-1449.
32. Pinkel D: Intravenous mercaptopurine: life begins at 40. J Clin Oncol 1993;11:1826-1831.
33. Sheu CJ, Moreland FM: Detection of dominant lethal mutation in mice after repeated low-dose administration of 6-mercaptopurine. Drug Chem Toxicol 1983;6:83-92.